## THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

## 1. A compound of the formula (I)

## wherein:

R<sub>2</sub> is selected from hydrogen, hydroxyl, O-alkyl, O-alkenyl, O-benzoyl, O-dibenzoyl, O-alkanoyl, O-alkenoyl, O-aryl, O-heterocyclic, O-heteroaryl or



wherein R<sub>5</sub> and R<sub>7</sub> are independently be selected from hydrogen, alkanoyl, alkenoyl, dibenzoyl, benzoyl or benzoyl alkyl substituted alkanoyl; R<sub>3</sub> is selected from hydroxyl, O-alkanoyl, O-alkenoyl, O-benzoyl, O-dibenzoyl, O-alkyl, O-alkenyl, O-aryl, O-heterocyclic or O-heteroaryl; R<sub>4</sub> is selected from -CH<sub>2</sub>OH, COOH, CH<sub>2</sub>OCOCH<sub>3</sub>, COO alkyl, COO aryl, CH<sub>2</sub>COO alkyl, COO-heterocyclic, COO-heteroaryl, CH<sub>2</sub>-O aryl, CH<sub>2</sub>O heterocyclic or CH<sub>2</sub>O heteroaryl;

R<sub>8</sub> is selected from hydrogen or



15

20

R<sub>7</sub> is selected from hydrogen or alkyl; or pharmaceutically acceptable salts thereof with the proviso that when R<sub>2</sub> is OH, R<sub>3</sub> is OH, R<sub>4</sub> is CH<sub>2</sub>OH, R<sub>6</sub> is xylopyranosyl, R<sub>1</sub> cannot be 4.

 A compound as claimed in claim 1 wherein R<sub>2</sub> is hydrogen, benzoyl, dibenzoyl, tigloyl or



wherein  $R_5$  and  $R_7$  are selected from hydrogen, tigloyl, benzoyl or benzoyl alkyl substituted alkanoyl.

- A compound as claimed in claim 1 wherein R<sub>3</sub> is selected from Oacetyl, O-benzoyl, O-dibenzoyl, O-lsobutyryl or O-tigloyl.
  - A compound as claimed in claim 1 wherein R₄ is selected from CH₂OH, O-acetyl or hydroxy.
  - 5. A compound as claimed in claim 1 wherein R₂ is arabino pyranosyl, 3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl-α-L-arabinopyranosyl, O-benzoyl, O-dibenzoyl, O-tigloyl, 3,4 dibenzoyl α-L-arabinopyranosyl, 3-(3-benzoyl-2 methylbutyryl-4-tigloyl-α-L-arabinopyranosyl, 3-tigloyl-4-(3-benzoyl-2 methylbutyryl)-α-L-arabinopyranosyl, 3-(3-benzoyl-2 methylbutyryl)-4-benzoyl-α-L-arabinopyranosyl, 0-3-(3-benzoyl-2 methylbutyryl)-4-benzoyl-α-L-arabinopyranosyl.
    - 6. A compound as claimed in claim 1 wherein R<sub>6</sub> is methyl.
    - 7. 3-O-ß-D-xylopyranosyl(1→3)-[ß-D-galactopyranosyl(1→2)]-ß-D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl-α-L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
- 25 8. 3-O-ß-D-xylopyranosyl(1→3)-[ß-D-galactopyranosyl(1→2)]-ß-D-

5

15

25

glucuronopyranosyl-21-O-benzoyl barringtogenol C;

- 9. 3-O-ß-D-xylopyranosyl(1→3)-[ß-D-galactopyranosyl(1→2)]-ß-D-glucuronopyranosyl-21-O-benzoyl-28-O-acetyl barringtogenol C;
- 10. 3-O-β-D-xylopyranosyl(1→3)-[β-D-galactopyranosyl(1→2)]-β-D-glucuronopyranosyl-21-O-benzoyl-22-O-isobutyryl barringtogenol C;
- 11. 3-O-β-D-xylopyranosyl(1→3)-[β-D-galactopyranosyl(1→2)]-β-D-methylglucuronopyranosyl-21,22-O-dibenzoyl barringtogenol C;
- 12. 3-O-β-D-xylopyranosyl(1→3)-[β-D-galactopyranosyl(1→2)]-β-D-glucuronopyranosyl-21, 22-O-dibenzoyl barringtogenol C;
- 13. 3-O-β-D-xylopyranosyl(1→3)-[β-D-galactopyranosyl(1→2)]-β-D-methylglucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
  - 14. 3-O-β-D-xylopyranosyl(1→3)-[β-D-galactopyranosyl(1→2)]-β-D-glucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;
  - 15. 3-O-ß-D-xylopyranosyl(1→3)-[ß-D-galactopyranosyl(1→2)]-ß-D-methylglucuronopyranosyl-21,22-O-tigloyl barringtogenol C;
  - 16. 3-O-ß-D-xylopyranosyl(1→3)-[ß-D-galactopyranosyl(1→2)]--D-glucuronopyranosyl-21,22-O-tigloyl barringtogenol C:
  - 17. 3-O-β-D-xylopyranosyl(1→3)-[β-D-galactopyranosyl(1→2)]-β-D-glucuronopyranosyl-22-O-benzoyl barringtogenol C;
- 18. 3-O-β-D-xylopyranosyl(1→3)-[βD-galactopyranosyl(1→2)]-β-D-glucuronopyranosyl-21-O-[3,4-dibenzoyl-α-L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
  - 19. 3-O-β-D-xylopyranosyl(1→3)-[β-D-galactopyranosyl(1→2)]-β-D-glucuronopyranosyl-21-O-[3,4-dibenzoyl-α-L-arabinopyranosyl]-28-O-acetyl barringtogenol C;
  - 20. 3-O-ß-D-xylopyranosyl(1→3)-[ß-D-galactopyranosyl(1→2)]-β-D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-tigloyl-α-L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
  - 21. 3-O-ß-D-xylopyranosyl(1→3)-[ß-D-galactopyranosyl(1→2)]-ß-D-
- 30 glucuronopyranosyl-21-O-[3-tigloyl-4-(3-benzoyl-2-methylbutyryl)-α-L-arabinopyranosyl]-22-O-acetyl barringtogenol C;
  - 22. 3-O-β-D-galactopyranosyl(1→2)-β-D-glucuronopyranosyl-21-O-[3-(3-

5

benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C; or

- 23. 3-O- $\$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl]-28-O-acetyl barringtogenol C.
- 24. A pharmaceutical composition for treatment and/or control of pain comprising a therapeutically effective amount of a compound of any one of claims 1 to 23 and a pharmaceutically acceptable carrier.
- 25. A pharmaceutical composition as claimed in claim 24 wherein the carrier is a pharmaceutically acceptable excipient.
  - 26. A method of treating and/or controlling pain which includes the step of administering to a subject in need of such treatment at least one compound as claimed in any one of claims 1 to 23.